Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, with approximately 20% of patients ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments. Genetic testing is a laboratory method ...

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical ...

The direct-to-consumer genetic ... also tests for two variants in genes that increase one's risk of colorectal cancer, though there are about 25 acquired gene mutations known to increase CRC ...

The modern-day paternity test compares a baby’s DNA profile to the potential father’s. How did we ever manage it before genetics ... specific blood types) in the child and using this ...

Using blood samples collected ... that allow diagnosis of CRC and precancerous polyps, respectively. Independent validation cohort testing demonstrated an exceptionally high accuracy of detection ...

The peer-reviewed manuscript, titled "A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch ... Around 75-95% of CRC cases occur in people with little or no genetic risk.

Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease ... The Guardant Reveal test is now covered by Medicare for use in the CRC surveillance setting ...

​Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets related to cancer-detection blood tests, according to court documents.

the whole genome DNA screening for 3D EpiSwitch biomarkers in blood has identified and validated two eight-marker signatures (EpiSwitch® NST) that allow diagnosis of CRC and precancerous polyps, ...